检测头颈癌预后性CD57+ T细胞的实用方法
头颈鳞状细胞癌复发影响近半数患者且降低生存,目前缺乏可靠预测机制。本研究开发了使用更少荧光抗体的流式细胞术组合,在手术治疗的HNSCC队列中验证其保留HD TEMRA细胞预测复发的能力,并发现口腔鳞癌患者仅用CD8+CD57+即可预测局部区域复发。
要点
- 简化流式panel保留HD TEMRA细胞预测HNSCC复发的预后价值
- 口腔鳞癌患者仅需CD8+CD57+即可预测局部区域复发
- HD TEMRA比例作为生物标志物有助于个体化治疗规划
核心结论
- 简化流式细胞术panel可有效检测HD TEMRA细胞并预测HNSCC疾病复发。
- 口腔鳞癌患者仅用CD8+CD57+识别HD TEMRA即可预测局部区域复发。
研究设计与样本
- 研究在手术治疗的HNSCC患者队列中开发并验证简化流式细胞术panel。
主要发现
- 以live CD8+CD28-CD57+识别HD TEMRA细胞可有效预测疾病复发。
- 口腔鳞癌患者仅用CD8+CD57+识别HD TEMRA即可预测局部区域复发。
关键数值与推荐
- HD TEMRA细胞定义为live CD8+CD28-CD57+细胞。
- 口腔鳞癌亚组中CD8+CD57+足以预测局部区域复发。
临床怎么用
- 简化panel提高HD TEMRA比例作为临床生物标志物的可行性。
- HD TEMRA比例可用于辅助HNSCC个体化治疗规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrence of head and neck squamous cell carcinoma (HNSCC) affects nearly half of patients and greatly reduces survival. There are currently no well-established mechanisms to predict which HNSCC patients will experience disease recurrence. We have previously shown that an elevated proportion of highly differentiated, CD57+ effector memory T (HD TEMRA) cells in circulation is associated with early recurrence and poor locoregional disease control in HNSCC patients. METHODS: Here, we present refined flow cytometry panels utilizing fewer fluorescent antibodies that retain the prognostic value of HD TEMRA cells in predicting HNSCC recurrence. RESULTS: In our cohort of surgically treated HNSCC patients, identifying HD TEMRA cells via flow cytometry as live CD8+ CD28- CD57+ cells effectively predicted disease recurrence. When assessing this cohort by disease subsite, we found that for patients with oral squamous cell carcinoma, identifying HD TEMRA cells by CD8+ CD57+ alone was sufficient for predicting locoregional disease recurrence. CONCLUSIONS: These refined panels enhance the clinical utility of HD TEMRA proportion as a biomarker due to their technical and analytic ease. Implementation of HD TEMRA cell proportion as a clinical biomarker could aid in personalized HNSCC treatment planning.
引用
- Brammer B, Kinney BLC, Kansal V, et al. A Practical Method for Detecting Prognostic CD57+ T Cells in Head and Neck Cancer. Head Neck. 2025. PMID: 41107054. doi:10.1002/hed.70074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。